Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive disorder that affects motor neurons. It is caused by mutations in the survival motor neuron gene 1 (SMN1). The SMN2 gene, which is the highly homologous SMN1 copy that is present in all the patients, is unable to prevent the disease. An SMN2 dosage method was applied to 45 patients with the three SMA types (I–III) and to four pairs of siblings with chronic SMA (II–III) and different phenotypes. Our results confirm that the SMN2 copy number plays a key role in predicting acute or chronic SMA. However, siblings with different SMA phenotypes show an identical SMN2 copy number and identical markers, indicating that the genetic background around the SMA locus is insufficient to account for the intrafamilial variability. In our results, age of onset appears to be the most important predictor of disease severity in affected members of the same family.Given that SMN2 is regarded as a target for potential pharmacological therapies in SMA, the identification of genetic factors other than the SMN genes is necessary to better understand the pathogenesis of the disease in order to implement additional therapeutic approaches.
Similar content being viewed by others
References
Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, Villanova M, Bertini E, Pini A, Neri G, Brahe C (2004) Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 12:59–65
Bouwsma G, Leschot NJ (1986) Unusual pedigree patterns in seven families with spinal muscular atrophy; further evidence for the allelic model hypothesis. Clin Genet 30:145–149
Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B (2003) Valproic acid increases the SMN2 protein level: a well–known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12:2481–2489
Bussaglia E, Tizzano EF, Illa I, Cervera C, Baiget M (1997) Cramps and minimal EMG abnormalities as preclinical manifestations of spinal muscular atrophy patients with homozygous deletions of the SMN gene. Neurology 48:1443–1445
Capon F, Levato C, Merlini L, Angelini C, Mostacciuolo ML, Politano L, Novelli G, Dallapiccola B (1996) Discordant clinical outcome in type III spinal muscular atrophy sibships showing the same deletion pattern. Neuromuscul Disord 6:261–264
Cobben JM, van der Steege G, Grootscholten P, et al. (1995) Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet 57:805–808
Cusco I, Barceló MJ, Baiget M, Tizzano E (2002) Implementation of SMA carrier testing in genetic laboratories: Comparison of two methods for quantifying the SMN1 gene. Hum Mutat 20:452–459
Cusco I, Lopez E, Soler–Botija C, Barcelo MJ, Baiget M, Tizzano EF (2003) A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c 0,399_402del AGAG, the most frequently found subtle mutation in the SMN1 gene. Hum Mutat 22:136–143
Emery AE (1971) The nosology of spinal muscular atrophies. J Med Genet 8:481–495
Feldkötter M, Schwarzer V, Wirth R, Wienker TF, Wirth B (2002) Quantitative Analyses of SMN1 and SMN2 Based on Real–Time LightCycler PCR: Fast and Highly Reliable carrier testing and Prediction of severity of Spinal Muscular Atrophy. Am J Hum Genet 70:358–368
Gomez R (1994) The clinical examination in Myology. In: Engel AG, Franzini–Armstrong C (eds) 2nd edition Mc Graw–Hill, New York 1:746–763
Hahnen E, Forkert R, Marke C, et al. (1995) Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet 10:1927–1933
Harada Y, Sutomo R, Sadewa AH, Akutsu T, Takeshima Y, Wada H, Matsuo M, Nishio H (2002) Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J Neurol 249:1211–1219
Helmken C, Hofmann Y, Schoenen F, Oprea G, Raschke H, Rudnik– Schoneborn S, Zerres K, Wirth B (2003) Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2–beta1. Hum Genet 114:11–21
Lefebvre S, Bürglen L, Beboullet S, et al, (1995) Identification and characterisation of a spinal muscular atrophydetermining gene. Cell 80:155–165
Munsat TL, Davies KE (1997) Spinal Muscular Atrophy, In: Emery AEH (ed) Diagnostic criteria for neuromuscular disorders, 2nd ed, London, UK: Royal Society of Medicine Press, pp 37–41
Roy N, Mahadevan MS, Mclean M, et al. (1995) The gene for neural apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80:167–178
Wang CH, Xu J, Carter TA, et al. (1996) Characterization of survival motor neuron (SMNT) gene deletions in asymptomatic carriers of spinal muscular atrophy. Hum Mol Genet 5:359–365
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cuscó, I., Barceló, M.J., Rojas–García, R. et al. SMN2 copy number predicts acute or chronic spinal muscular atrophy but does not account for intrafamilial variability in siblings. J Neurol 253, 21–25 (2006). https://doi.org/10.1007/s00415-005-0912-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0912-y